Sanofi bags €300m from US investor Blackstone

Sanofi has secured money from Blackstone Life Sciences to speed up development of its daratumumab competitor isatuximab in multiple myeloma.

Read more

Life-sciences hub Saxony: a driver of innovation for cell and gene therapy

Saxony has established itself as a dynamic life-sciences hub and provides an attractive environment for investors and start-ups The ‘SaxoCell’ network and CMI major research centre are furthering innovations in cell and gene therapy Interdisciplinary co-operation offers huge growth opportunities for applications such as point-of-care diagnostics Leipzig as host of BIO-Europe 2022

Read more

Join 900 US CEOs protest against Ukraine invasion

US Life Science leaders pledge to economically disengage from Russia.

Read more

Join 900 US CEOs protest against Ukraine war

US Life Science leaders pledge to economically disengage from Russia.

Read more

Scenic Biotech BV announces $31m financing

Scenic Biotech BV will use an incoming $31m (€28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease.

·      

Read more

Kurma Partners closes growth fund at €160m

French venture capital expert Kurma Partners has closed its Growth Opportunities Fund at €160m and targets a final closing at €250m.

Read more

mRNA for Africa

Moderna will build its first mRNA production facility in Kenya, investing up to US$500m. 

Read more
PhoreMost

PhoreMost with new CEO

Since the beginning of March, Dr Neil Torbett has been the new Chief Executive Officer of Cambridge-based PhoreMost Ltd.

Read more

Epsilogen raise £30.75m in Series B financing

IgE cancer antibody specialist Epsilogen Ltd has closed a £30.75m round  led by Novartis Venture Fund to advance Phase Ib studies with MOv18 IgE in platinum-resistant ovarian cancer.

Read more

Syndesi swallowed by Abbvie

AbbVie has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.

Read more